US20030028012A1 - Polynucleotide synthesis - Google Patents
Polynucleotide synthesis Download PDFInfo
- Publication number
- US20030028012A1 US20030028012A1 US10/245,211 US24521102A US2003028012A1 US 20030028012 A1 US20030028012 A1 US 20030028012A1 US 24521102 A US24521102 A US 24521102A US 2003028012 A1 US2003028012 A1 US 2003028012A1
- Authority
- US
- United States
- Prior art keywords
- phosphoramidyl
- substrate
- hydroxy
- protected alcohol
- nucleoside
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108091033319 polynucleotide Proteins 0.000 title claims abstract description 44
- 102000040430 polynucleotide Human genes 0.000 title claims abstract description 44
- 239000002157 polynucleotide Substances 0.000 title claims abstract description 44
- 238000003786 synthesis reaction Methods 0.000 title description 11
- 230000015572 biosynthetic process Effects 0.000 title description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 78
- 238000000034 method Methods 0.000 claims abstract description 61
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 48
- -1 phospho Chemical class 0.000 claims abstract description 40
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical class OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 claims abstract description 37
- 229910019142 PO4 Inorganic materials 0.000 claims abstract description 22
- 230000008878 coupling Effects 0.000 claims abstract description 18
- 238000010168 coupling process Methods 0.000 claims abstract description 18
- 238000005859 coupling reaction Methods 0.000 claims abstract description 18
- 239000010452 phosphate Substances 0.000 claims abstract description 17
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims abstract description 16
- 150000001875 compounds Chemical class 0.000 claims abstract description 11
- 238000004519 manufacturing process Methods 0.000 claims abstract description 10
- 230000003301 hydrolyzing effect Effects 0.000 claims abstract description 3
- 239000000758 substrate Substances 0.000 claims description 102
- 239000002777 nucleoside Substances 0.000 claims description 53
- 238000010511 deprotection reaction Methods 0.000 claims description 44
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 33
- 235000021317 phosphate Nutrition 0.000 claims description 20
- 108091034117 Oligonucleotide Proteins 0.000 claims description 12
- 150000008300 phosphoramidites Chemical class 0.000 claims description 12
- 230000007062 hydrolysis Effects 0.000 claims description 9
- 238000006460 hydrolysis reaction Methods 0.000 claims description 9
- 230000001590 oxidative effect Effects 0.000 claims description 8
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 5
- 150000007942 carboxylates Chemical group 0.000 claims description 5
- 238000003776 cleavage reaction Methods 0.000 claims description 5
- AQSJGOWTSHOLKH-UHFFFAOYSA-N phosphite(3-) Chemical class [O-]P([O-])[O-] AQSJGOWTSHOLKH-UHFFFAOYSA-N 0.000 claims description 5
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims description 5
- 230000007017 scission Effects 0.000 claims description 5
- 150000002243 furanoses Chemical class 0.000 claims description 3
- 150000003214 pyranose derivatives Chemical class 0.000 claims description 3
- 230000002194 synthesizing effect Effects 0.000 claims description 3
- 230000002378 acidificating effect Effects 0.000 claims description 2
- 150000001717 carbocyclic compounds Chemical class 0.000 claims 1
- 150000002391 heterocyclic compounds Chemical class 0.000 claims 1
- 238000003491 array Methods 0.000 abstract description 23
- 125000006239 protecting group Chemical group 0.000 description 22
- 125000005647 linker group Chemical group 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 125000003729 nucleotide group Chemical group 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 229920001222 biopolymer Polymers 0.000 description 11
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- 239000002773 nucleotide Substances 0.000 description 10
- 125000004430 oxygen atom Chemical group O* 0.000 description 10
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 125000000524 functional group Chemical group 0.000 description 6
- 230000003647 oxidation Effects 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 238000013459 approach Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 0 *C1C(B)OC(COC)C1OP([13*])([14*])=C Chemical compound *C1C(B)OC(COC)C1OP([13*])([14*])=C 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 238000000151 deposition Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 125000002541 furyl group Chemical group 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 150000004713 phosphodiesters Chemical class 0.000 description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000003158 alcohol group Chemical group 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- RKVHNYJPIXOHRW-UHFFFAOYSA-N 3-bis[di(propan-2-yl)amino]phosphanyloxypropanenitrile Chemical compound CC(C)N(C(C)C)P(N(C(C)C)C(C)C)OCCC#N RKVHNYJPIXOHRW-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 125000006241 alcohol protecting group Chemical group 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 150000003536 tetrazoles Chemical class 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- LOVPHSMOAVXQIH-UHFFFAOYSA-N (4-nitrophenyl) hydrogen carbonate Chemical group OC(=O)OC1=CC=C([N+]([O-])=O)C=C1 LOVPHSMOAVXQIH-UHFFFAOYSA-N 0.000 description 1
- KMEMIMRPZGDOMG-UHFFFAOYSA-N 2-cyanoethoxyphosphonamidous acid Chemical compound NP(O)OCCC#N KMEMIMRPZGDOMG-UHFFFAOYSA-N 0.000 description 1
- 125000002103 4,4'-dimethoxytriphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)(C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H])C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 1
- 108091027075 5S-rRNA precursor Proteins 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000005599 alkyl carboxylate group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 125000005929 isobutyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])OC(*)=O 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 125000004437 phosphorous atom Chemical group 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000001725 pyrenyl group Chemical group 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000004187 tetrahydropyran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/11—Compounds covalently bound to a solid support
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
Definitions
- This invention relates to arrays, particularly polynucleotide arrays such as DNA arrays, which are useful in diagnostic, screening, gene expression analysis, and other applications.
- Polynucleotide arrays such as DNA or RNA arrays
- Such arrays include regions of usually different sequence polynucleotides arranged in a predetermined configuration on a substrate. These regions (sometimes referenced as “features”) are positioned at respective locations (“addresses”) on the substrate.
- the arrays when exposed to a sample, will exhibit an observed binding pattern. This binding pattern can be detected upon interrogating the array.
- all polynucleotide targets for example, DNA
- a suitable label such as a fluorescent compound
- Biopolymer arrays can be fabricated by depositing previously obtained biopolymers onto a substrate, or by in situ synthesis methods.
- the in situ fabrication methods include those described in WO 98/41531 and the references cited therein.
- the in situ method for fabricating a polynucleotide array typically follows, at each of the multiple different addresses at which features are to be formed, the same conventional iterative sequence used in forming polynucleotides on a support by means of known chemistry. Typically these methods use a nucleoside reagent of the formula:
- A represents H or an optionally protected hydroxyl group
- B is a purine or pyrimidine base whose exocyclic amine functional group is optionally protected;
- Q is a conventional protective group for the 5′—OH functional group
- R 13 represents H and R 14 represents a negatively charged oxygen atom
- R 13 is an oxygen atom and R 14 represents either an oxygen atom or an oxygen atom carrying a protecting group;
- R 13 is an oxygen atom carrying a protecting group and R 14 is either a hydrogen or a di-substituted amine group.
- R 13 is an oxygen atom carrying a protecting group and R 14 is either a halogen
- the method is known as the phosphite method and, when R 14 is a leaving group of the disubstituted amine type, the method is known as the phosphoramidite method.
- nucleoside-modified substrate in subsequent iterations; (b) optionally, but preferably, blocking unreacted hydroxyl groups on the substrate bound nucleoside; (c) oxidizing the phosphite linkage of step (a) to form a phosphate linkage; and (d) removing the protecting group (“deprotection”) from the now substrate bound nucleoside coupled in step (a), to generate a reactive site for the next cycle of these steps.
- the functionalized support (in the first cycle) or deprotected coupled nucleoside (in subsequent cycles) provides a substrate bound moiety with a linking group for forming the phosphite linkage with a next nucleoside to be coupled in step (a).
- Final deprotection of nucleoside bases can be accomplished using alkaline conditions such as ammonium hydroxide, in a known manner.
- 4,816,571 suggests using a phosphite monoester capping reagent to form, along with the free hydroxy of the failed sequence, a phosphite triester blocking group.
- a capping reagent can leave some portions of the surface not carrying the desired polynucleotide sequences, with a different terminal group (a phosphite triester) than other portions since removal of the phosphite (de-capping) is relatively inefficient.
- interfeature spaces spaces between the individual features
- capping is performed by exposing an entire functionalized substrate (such as by flooding) with the capping reagent.
- some portions of the functionalized surface may be capped but not others. Due to such differences in interfeature surface composition (specifically, the functional groups left at the end the failed sequences or functionalizing group), background absorption of polynucleotides in a sample being tested onto interfeature areas may vary across the substrate, making identification of a features to which polynucleotides have bound, more difficult.
- automated systems are used to detect such features, based on patterns observed on the array following exposure to a sample.
- RNA hydrolysis it is also known in the context of RNA hydrolysis generally, and in the context of preparing a “universal” solid support upon which oligonucleotides can be synthesized, that a ⁇ -phosphotriester group (in relation to a an ester group) of a molecule used to link the growing oligonucleotide to a support, can be hydrolyzed so as to cleave the linker from the support and the phosphate from the linker to provide a 3′ hydroxy on the growing oligonucleotide.
- a ⁇ -phosphotriester group in relation to a an ester group
- the present invention provides a method of comprising coupling coupling a hydroxy group of a moiety to a ⁇ -phospho or ⁇ -phosphite (such as a ⁇ -phosphoramidyl), protected alcohol, so as to form the corresponding phosphate or phosphite between the hydroxy and phospho or phosphite groups.
- a ⁇ -phospho or ⁇ -phosphite such as a ⁇ -phosphoramidyl
- the invention may include the step of oxidizing any phosphorous ester linkage formed other than a phosphate (for example, phosphite) to the corresponding phosphate.
- a phosphate for example, phosphite
- the resulting compound (containing the phosphate group) may then be hydrolyzed to deprotect the protected alcohol and cleave the phosphate from the moiety so as to regenerate the hydroxy group of the moiety.
- the present invention provides a method of protecting and de-protecting a hydroxy group of a moiety.
- the hydroxy group may be protected as described above, and de-protected by hydrolyzing the resulting compound to deprotect the protected alcohol and cleave the phosphate from the moiety so as to regenerate the hydroxy group of the moiety.
- the de-protection may be performed under suitable conditions, such as those described in deBear et al., cited above.
- the hydrolysis may be performed under alkaline conditions.
- the above method is applied to a method of synthesizing oligonucleotides on a substrate carrying substrate bound moieties each with a hydroxy group (such as a functionalized substrate surface or a hydroxy group of a substrate bound nucleotide).
- a first nucleoside carrying a phospho or phosphite group is coupled to the hydroxy group of at least some of the substrate bound moieties in the usual manner.
- the first nucleoside has a protected hydroxy which can be deprotected under first deprotection conditions.
- this coupling step results in forming the corresponding phosphite between the hydroxy groups of the substrate bound moieties and the phosphoramidyl groups of the first phosphoramidite.
- At least some of the substrate bound moieties which failed to couple with the nucleoside phosphoramidite are protected by exposing them to a ⁇ - or ⁇ -phosphoramidyl, protected alcohol, in the manner described above, which protected alcohol can be deprotected under second deprotection conditions but not the first deprotection conditions.
- this forms the corresponding phosphite between the hydroxy of those substrate bound moieties, and phosphoramidyl group of the ⁇ - or ⁇ -phosphoramidyl, protected alcohol.
- the oligonucleotide synthesis method of the present invention may include, following the foregoing, a deprotection step is performed in which the substrate is exposed to the first deprotection conditions to deprotect the protected hydroxy of the coupled nucleoside in a manner already described.
- the sequence of the coupling and de-protecting steps may be repeated as often as required to form a desired polynucleotide, with the deprotected hydroxy of the coupled nucleoside from the deprotection step in one cycle of the steps, serving as the hydroxy group of substrate bound moieties in the next cycle.
- the substrate may be exposed to the second deprotection conditions to de-protect failed sequences by hydrolysis in the manner already described, so as to regenerate the hydroxy group of the substrate bound moiety.
- the substrate may be exposed to the second deprotection conditions to de-protect failed sequences by hydrolysis in the manner already described, so as to regenerate the hydroxy group of the substrate bound moiety.
- an oxidation step may be provided to oxidize internucleoside phosphites to the more stable corresponding phosphates, and one or more washing steps may also be provided.
- the present invention further includes, in another aspect, a method of fabricating an addressable array of polynucleotides on a substrate carrying substrate bound moieties each with a hydroxy group.
- This method includes, at each of multiple different substrate addresses, executing the above described olumbleucleotide synthesis method of the present invention (particularly, including the described protecting and de-protecting steps).
- the phosphoramidites to be coupled at respective addresses may, for example, be deposited as droplets at those addresses, and wherein in the protecting step at least inter-address areas (and preferably both address and inter-address areas) are exposed to the ⁇ - or ⁇ -phospho or phosphite (for example, phosphoramidyl), protected alcohol.
- the various aspects of the present invention can provide any one or more of a number of useful benefits.
- an alternative method of capping failed sequences in polynucleotide formation is provided which does not require use of acetic anhydride.
- the method can be used in the fabrication of polynucleotide arrays and can provide failed sequences and interfeature areas with a functional group of the same type as provided by the functionalized surface.
- FIGS. 1 and 2 illustrate known schemes in the use of universal supports for polynucleotide synthesis, as discussed in the “Background” section above;
- FIG. 3 illustrates a substrate carrying multiple arrays, such as may be fabricated by methods of the present invention
- FIG. 4 is an enlarged view of a portion of FIG. 3 showing multiple spots or features of one array
- FIG. 5 is an enlarged illustration of a portion of the substrate of FIG. 3;
- FIG. 6 is a schematic illustrating in general a capping and de-capping method of the present invention.
- FIG. 7 is a schematic illustrating a specific capping and de-capping method of the present invention.
- a “biopolymer” is a polymer of one or more types of repeating units. Biopolymers are a type of polymer found in biological systems and particularly include peptides or polynucleotides, as well as such compounds composed of or containing amino acid or nucleotide analogs or non-nucleotide groups. This includes polynucleotides in which the conventional backbone has been replaced with a non-naturally occurring or synthetic backbone, and nucleic acids in which one or more of the conventional bases has been replaced with a synthetic base capable of participating in Watson-Crick type hydrogen bonding interactions.
- Polynucleotides include single or multiple stranded configurations, where one or more of the strands may or may not be completely aligned with another. While probes and targets of the present invention will typically be single-stranded, this is not essential.
- a “nucleotide” refers to a sub-unit of a nucleic acid and has a phosphate group, a 5 carbon sugar and a nitrogen containing base, as well as analogs of such sub-units.
- a “biopolymer” includes DNA (including cDNA), RNA and oligonucleotides, regardless of the source.
- oligonucleotide generally refers to a nucleotide multimer of about 10 to 100 nucleotides in length, while a “polynucleotide” includes a nucleotide multimer having any number of nucleotides.
- a “biomonomer” references a single unit, which can be linked with the same or other biomonomers to form a biopolymer (for example, a single amino acid or nucleotide with two linking groups one or both of which may have removable protecting groups).
- a biomonomer fluid or biopolymer fluid reference a liquid containing either a biomonomer or biopolymer, respectively (typically in solution).
- An “array”, unless a contrary intention appears, includes any one or two dimensional arrangement of addressable regions bearing a particular chemical moiety to moieties (for example, biopolymers such as polynucleotide sequences) associated with that region.
- An array is “addressable” in that it has multiple regions of different moieties (for example, different polynucleotide sequences) such that a region (a “feature” or “spot” of the array) at a particular predetermined location (an “address”) on the array will detect a particular target or class of targets (although a feature may incidentally detect non-targets of that feature).
- the “target” will be referenced as a moiety in a mobile phase (typically fluid), to be detected by probes (“target probes”) which are bound to the substrate at the various regions.
- probes typically fluid
- either of the “target” or “target probes” may be the one which is to be evaluated by the other (thus, either one could be an unknown mixture of polynucleotides to be evaluated by binding with the other).
- An “array layout” refers to one or more characteristics of the array, such as feature positioning, feature size, and some indication of a moiety at a given location. “Hybridizing” and “binding”, with respect to polynucleotides, are used interchangeably.
- a “phospho” group includes a phosphodiester, phosphotriester, and H-phosphonate groups as defined in connection with formula (I) above, while a “phosphite” includes a phosphoramidite (in the case of either a phospho or phosphite group, a moiety other than the illustrated substituted 5-membered furyl ring may be attached to O of the phospho or phosphite group which links between the furyl ring shown in formula (I) and the P atom).
- a “lower” alkyl, carboxylate or other “lower” group references such a group having from 1 to 6 carbon atoms.
- a “protecting group” is used in the conventional chemical sense to reference a group which reversibly renders unreactive a functional group under specified conditions of a desired reaction. After the desired reaction, protecting groups may be removed to deprotect the protected functional group.
- the —OH group of a nucleoside monomer typically, the 3′ or 5′ —OH of a nucleoside phosphoramidite
- the —OH group of a nucleoside monomer typically, the 3′ or 5′ —OH of a nucleoside phosphoramidite
- —OH of the nucleoside monomer which is generally only deprotected after the desired polynucleotide synthesis is complete is referenced as an “alcohol” group (which is typically protected until after such completion).
- All protecting groups should be removable (and hence, labile) under conditions which do not degrade a substantial proportion of the polynucleotides being synthesized. It is also possible in the present invention that steps may be executed in different sequence where this is logically possible. However, the sequence described below is preferred.
- typically methods and apparatus of the present invention generate or use a contiguous planar substrate 10 carrying one or more arrays 12 disposed across a first surface 11 a of substrate 10 and separated by inter-array areas 13 .
- the arrays on substrate 10 can be designed for testing against any type of sample, whether a trial sample, reference sample, a combination of them, or a known mixture of polynucleotides (in which latter case the arrays may be composed of features carrying unknown sequences to be evaluated). While ten arrays 12 are shown in FIG. 5 and the different embodiments described below may use substrates with particular numbers of arrays, it will be understood that substrate 10 and the embodiments to be used with it, may use any number of desired arrays 12 .
- substrate 10 may be of any shape, and any apparatus used with it adapted accordingly.
- any or all of arrays 12 may be the same or different from one another and each will contain multiple spots or features 16 of biopolymers in the form of polynucleotides.
- a typical array may contain from more than ten, more than one hundred, more than one thousand or ten thousand features, or even more than from one hundred thousand features. All of the features 16 may be different, or some or all could be the same.
- Each feature carries a predetermined polynucleotide (which includes the possibility of mixtures of polynucleotides).
- A, C, G, T represent the usual nucleotides, while L represents a linker bound to substrate 10 .
- L represents a linker bound to substrate 10 .
- arrays 12 are formed by the in situ method by depositing droplets of reagents in each step such as by using a pulse jet such as an inkjet type head, such interfeature areas 17 will typically be present.
- the method of the present invention may use a ⁇ - or ⁇ -phospho or phosphite, protected alcohol.
- ⁇ -phospho or ⁇ -phosphite, protected alcohols have the following structure:
- Y—O— is a phospho or phosphite group as defined above; any of R2, R3, R4 or R5 may be the same or different and may be selected from H, substituted or unsubstituted alkyl or alkoxyl groups (particularly lower alkyl groups), or any two of them may together form a carbocyclic ring or heterocyclic ring (including those having one or two heteroatoms selected from N or O) such as a five to seven membered ring (for example, furyl); and X represents an alcohol protecting group.
- ⁇ -phospho or ⁇ -phosphite compounds have the same formula as (II) above, except that there is an additional C (substituted or unsubstituted with one to two groups, the same or different selected from any of those groups which R2 to R5 may represent) between the Cs to which R2 and R4 are bonded.
- Particularly preferred are those compounds of formula (II) in which two of R2 to R5 form a ring, particularly a 5 membered heterocyclic ring, such as furyl or pyryl (particularly where the compound is a furanose, or pyranose derivative).
- Y—O— and X—O— are cis with respect to one another.
- Suitable protecting groups on the alcohol include those such as described in “Protective groups in organic synthesis” by Theodora W. Greene and Peter G. M. Wuts , Wiley-interscience ISBN 0-471-62301-6 p68-117.
- the protecting group on the alcohol group substantially prevents one monomer from linking with another through that alcohol group during growing of the polymer chain.
- Particular examples of compounds of formulae (II) may include ⁇ - or ⁇ -phosphoramidyl, protected alcohols, such as 3-carboxylate-4-phosphoramidylfuran, or 2,5-dialkoxy-3-carboxylate-4-phosphoramidylfuran, or any of those compounds illustrate below:
- X may, for example, be an H-phosphonate, Me-phosphonate, or phosphodiester group.
- the ⁇ - or ⁇ -phospho or phosphite, protected alcohols can be prepared by methods such as described by Toshiki Tanaka and Robert Letsinger, Nucleic Acids Research, 10, 3249-3260, 1982.
- the ⁇ - or ⁇ -phosphoramidyl, protected alcohols in particular can be prepared by the method described in column 11 and 12 of U.S. Pat. No. 5,681,945 up to product 2, then the remaining alcohol is converted to the cyanoethyl phosphoramidite using 2-cyanoethyl-N,N,N′,N′-tetraisopropylphosphorodiamidite (A. Kraszewski, K. E.
- the mixture is diluted with CH 2 Cl 2 (20 ml) and extracted with 2% aqueous Na 2 CO 3 (30 ml) followed by brine (30 ml). The aqueous layers are back extracted with CH 2 Cl 2 (30 ml). The combined organic layers are dried over Na 2 SO 4 . The organic fraction is concentrated to 15 ml and product is precipitated from cold hexane. The precipitate is dried under vaccum.
- a typical execution of a method of the present invention is illustrated using a ⁇ -phospho or ⁇ -phosphite compound of formula (II).
- substrate 10 will have been functionalized by providing it with substrate bound moieties with hydroxy groups. Suitable techniques for functionalizing substrates with such linking moieties are described, for example, in Southern, E. M., Maskos, U. and Elder, J. K., Genomics, 13, 1007-1017, 1992.
- this step is normally carried out by exposing the substrate 10 (in particular, first surface 11 a of substrate 10 ) to functionalizing reagents as described in the foregoing references.
- a nucleoside phospho or phosphite compound is then deposited as a droplet of solution onto each address on substrate 10 at which it is desired to form a features 16 , using any suitable droplet deposition technique as discussed above, such as a pulse jet (for example, and inkjet head).
- a nucleoside compound typically has the phospho or phosphite group at one of the 3′ or 5′ positions, depending upon which direction (3′ to 5′, or 5′ to 3′) it is desired to have the polynucleotide synthesis proceed, and a protected hydroxy group at the other one of those positions.
- Nucleoside phosphoramidites are preferred. Suitable protecting groups are described in “Protective Groups in Organic Synthesis” by T.
- the protecting group should be capable of removal to deprotect the hydroxy group, under first deprotection conditions.
- the first deprotection conditions preferably are acidic conditions, and thus acid labile protecting groups are preferred.
- Acid labile protecting groups include those such as tetrahydropyranyl groups, e.g.
- the preferred acid labile protecting group is a dimethoxytrityl group, especially 4,4′-dimethoxytrityl. Conventional known reaction conditions may be used.
- the nucleoside compound is coupled to the hydroxy groups of at least some of the substrate bound linking groups, by forming the corresponding phospho or phosphite between the hydroxy groups of the substrate bound linkers and the phospho or phosphite group (for example, phosphoramidyl group) of the nucleoside compound.
- the reaction is complete very rapidly at room temperature of about 20° C. (for example, in one or two seconds).
- the coupling product is then oxidized using known conditions (described in one or more of the references cited above) to form the more stable corresponding phosphate bond between the nucleoside and linker.
- This is preferably performed by exposing substrate 10 (in particular, the entire first surface 11 a ) to the oxidizing solution, for example, by flowing such a solution across first surface 11 a . Note that this oxidation step is optional, although preferred.
- the capping of substrate bound linkers which failed to couple with a nucleoside compound can then be accomplished by exposing substrate 10 (in particular, the entire first surface 11 a ) to such reagent. This also is preferably accomplished by flowing a solution containing any of the capping reagents of formula (II) described above across first surface 11 a .
- Suitable solvents and reactions conditions include any of those which may be used to couple analogous nucleoside phospho or phosphite compounds to the linker, as described above. By analogous in this context, is referenced the same phospho or phosphite group being present.
- the alcohol protecting group, X should be one which is removed under second deprotection conditions but not removed under the first deprotection conditions.
- the second deprotection conditions are preferably alkaline, and thus X is preferably an alkaline labile deprotecting group. Suitable alkaline deprotecting groups are also described in “Protective Groups in Organic Synthesis”, supra.
- protecting groups X include benzoyl, acetyl, p-nitrophenyl carbonate groups, silyl protecting groups (for example, as dimethyl silyl) which can be removed with a fluoride anion such as tetrabutylammonium fluoride.
- a fluoride anion such as tetrabutylammonium fluoride.
- Particularly preferable are ones which provide, on the protected alcohol, a carboxylate group such as an alkyl carboxylate group (particularly a lower carboxylate group), such as acetate.
- substrate 10 may then be exposed to the first deprotection conditions (preferably by exposure to an acidic solution as already described), to deprotect the protected 3′ or 5′ hydroxy of the coupled nucleoside.
- the required solution is, for example, flowed across first surface 11 a .
- the steps of coupling, oxidation, capping, and deprotection of the coupled nucleoside may then be repeated until each feature 16 has the desired polynucleotide sequence. Note that in each repetition of the cycle of steps, the deprotected hydroxy group of a coupled nucleoside in a given cycle, serves as the hydroxy group of substrate bound moieties in the next cycle.
- the substrate 10 (particularly first surface 11 a ) is exposed to the second deprotection conditions. This also may be done by flowing the required alkaline solution across the entire first surface 11 a . As a result, failed sequences resulting from each cycle of the steps, will be deprotected, as illustrated in FIG. 6, by hydrolysis to deprotect the protected alcohol of such sequences and cleave the phosphate from the substrate bound moiety (whether a nucleotide or linker) so as to regenerate the hydroxy group of the substrate bound moiety.
- FIG. 7 A particular example of the method of the present invention is illustrate in FIG. 7 (in which “R” is any one of the lower alkyls, particularly methyl).
- the illustrate steps may be executed as follows.
- an equal amount of a solution of a capping phosphoramidite and an activator such as tetrazole
- the solutions are either premixed or mixed on the surface.
- an oxidation solution is flooded over the surface.
- the DNA array is removed from the synthesizer and is dipped in 600 ml of a 1:1 solution of a 40% methylamine in water and 28% ammonia in water.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
A method including coupling the moiety to a phospho or phosphite derivative of a protected alcohol, so as to form the corresponding phosphate or phosphite between the hydroxy and phospho or phosphite groups. The hydroxy group may be later de-protected by hydrolyzing the resulting compound to deprotect the protected alcohol and cleave the phosphate from the moiety so as to regenerate the hydroxy group of the moiety. The method has particular application to fabrication of addressable polynucleotide arrays and allows failed sequences, as well as inter-feature regions, to be left with a free hydroxy group at the ends of the molecules (failed sequences or linkers) at such locations.
Description
- This application is a continuation of allowed U.S. patent application Ser. No. 09/420099 filed Oct. 18, 1999 by the same inventor (expected to issue as U.S. Pat. No. 6,451,998 on Sept. 17, 2002), and from which priority is claimed under 35 U.S.C. 120. The foregoing application is incorporated herein by reference.
- This invention relates to arrays, particularly polynucleotide arrays such as DNA arrays, which are useful in diagnostic, screening, gene expression analysis, and other applications.
- Polynucleotide arrays (such as DNA or RNA arrays), are known and are used, for example, as diagnostic or screening tools. Such arrays include regions of usually different sequence polynucleotides arranged in a predetermined configuration on a substrate. These regions (sometimes referenced as “features”) are positioned at respective locations (“addresses”) on the substrate. The arrays, when exposed to a sample, will exhibit an observed binding pattern. This binding pattern can be detected upon interrogating the array. For example all polynucleotide targets (for example, DNA) in the sample can be labeled with a suitable label (such as a fluorescent compound), and the fluorescence pattern on the array accurately observed following exposure to the sample. Assuming that the different sequence polynucleotides were correctly deposited in accordance with the predetermined configuration, then the observed binding pattern will be indicative of the presence and/or concentration of one or more polynucleotide components of the sample.
- Biopolymer arrays can be fabricated by depositing previously obtained biopolymers onto a substrate, or by in situ synthesis methods. The in situ fabrication methods include those described in WO 98/41531 and the references cited therein. The in situ method for fabricating a polynucleotide array typically follows, at each of the multiple different addresses at which features are to be formed, the same conventional iterative sequence used in forming polynucleotides on a support by means of known chemistry. Typically these methods use a nucleoside reagent of the formula:
- in which:
- A represents H or an optionally protected hydroxyl group;
- B is a purine or pyrimidine base whose exocyclic amine functional group is optionally protected;
- Q is a conventional protective group for the 5′—OH functional group;
- x=O or 1 provided:
- a) when x=1:
- R 13 represents H and R14 represents a negatively charged oxygen atom; or
- R 13 is an oxygen atom and R14 represents either an oxygen atom or an oxygen atom carrying a protecting group; and
- b) when x=0, R 13 is an oxygen atom carrying a protecting group and R14 is either a hydrogen or a di-substituted amine group.
- When x is equal to 1, R 13 is an oxygen atom and R14 is an oxygen atom, the method is in this case the so-called phosphodiester method; when R14 is an oxygen atom carrying a protecting group, the method is in this case the so-called phosphotriester method.
- When x is equal to 1, R 13 is a hydrogen atom and R14 is a negatively charged oxygen atom, the method is known as the H-phosphonate method.
- When x is equal to 0, R 13 is an oxygen atom carrying a protecting group and R14 is either a halogen, the method is known as the phosphite method and, when R14 is a leaving group of the disubstituted amine type, the method is known as the phosphoramidite method.
- The conventional sequence used to prepare an oligonucleotide using reagents of the type of formula (I), basically follows the following steps: (a) coupling a selected nucleoside through a phosphite linkage to a functionalized support in the first iteration, or a nucleoside bound to the substrate (i.e. the nucleoside-modified substrate) in subsequent iterations; (b) optionally, but preferably, blocking unreacted hydroxyl groups on the substrate bound nucleoside; (c) oxidizing the phosphite linkage of step (a) to form a phosphate linkage; and (d) removing the protecting group (“deprotection”) from the now substrate bound nucleoside coupled in step (a), to generate a reactive site for the next cycle of these steps. The functionalized support (in the first cycle) or deprotected coupled nucleoside (in subsequent cycles) provides a substrate bound moiety with a linking group for forming the phosphite linkage with a next nucleoside to be coupled in step (a). Final deprotection of nucleoside bases can be accomplished using alkaline conditions such as ammonium hydroxide, in a known manner.
- The foregoing methods of preparing polynucleotides are described in detail, for example, in Caruthers, Science 230: 281-285, 1985; Itakura et al., Ann. Rev. Biochem. 53: 323-356; Hunkapillar et al., Nature 310: 105-110, 1984; and in “Synthesis of Oligonucleotide Derivatives in Design and Targeted Reaction of Oligonucleotide Derivatives,” CRC Press, Boca Raton, Fla., pages 100 et seq., U.S. Pat. No. 4,458,066, U.S. Pat. No. 4,500,707, U.S. Pat. No. 5,153,319, U.S. Pat. No. 5,869,643, EP 0294196, and elsewhere The phosphoramidite and phosphite triester approaches are most broadly used, but other approaches include the phosphodiester approach, the phosphotriester approach and the H-phosphonate approach.
- In the case of array fabrication, different monomers may be deposited at different addresses on the substrate during any one iteration so that the different features of the completed array will have different desired biopolymer sequences. One or more intermediate further steps may be required in each iteration, such as the conventional oxidation and washing steps.
- While each iteration of the foregoing sequence can have a very high yield (over 90%), there is still a small portion of the substrate bound moiety with unreacted linking groups (referenced together herein as “failed sequences”). It is known to cap such failed sequences to avoid the growth of undesired polynucleotide sequences from them. Capping compounds are described in the above mentioned references. A conventional capping compound is acetic anhydride which forms an acetate in conjunction with the hydroxy group of the substrate bound moiety. However, the yield of the capping reaction using acetic anhydride is relatively low. U.S. Pat. No. 4,816,571 suggests using a phosphite monoester capping reagent to form, along with the free hydroxy of the failed sequence, a phosphite triester blocking group. However, the present invention recognizes that in the fabrication of addressable arrays, use of such a capping reagent can leave some portions of the surface not carrying the desired polynucleotide sequences, with a different terminal group (a phosphite triester) than other portions since removal of the phosphite (de-capping) is relatively inefficient. This is particularly the case where an array is formed by a method which leaves spaces between the individual features (“interfeature spaces”), such as deposition of droplets of reagents at the desired feature locations, and when capping is performed by exposing an entire functionalized substrate (such as by flooding) with the capping reagent. In such cases, some portions of the functionalized surface may be capped but not others. Due to such differences in interfeature surface composition (specifically, the functional groups left at the end the failed sequences or functionalizing group), background absorption of polynucleotides in a sample being tested onto interfeature areas may vary across the substrate, making identification of a features to which polynucleotides have bound, more difficult. This may be particularly the case where automated systems are used to detect such features, based on patterns observed on the array following exposure to a sample.
- It is also known in the context of RNA hydrolysis generally, and in the context of preparing a “universal” solid support upon which oligonucleotides can be synthesized, that a β-phosphotriester group (in relation to a an ester group) of a molecule used to link the growing oligonucleotide to a support, can be hydrolyzed so as to cleave the linker from the support and the phosphate from the linker to provide a 3′ hydroxy on the growing oligonucleotide. Such a scheme is disclosed in U.S. Pat. No. 5,681,945 and is illustrated in FIG. 1. Similarly, deBear et al. in Nucleosides & Nucleotides, 6(5), 821-830 (1987) also discloses preparation of a universal solid support involving the sequence illustrated in FIG. 2. Additionally, the reaction energy profile involved in reactions of the foregoing type, has been disclosed by Uchimaru et al., Biochemical and Biophysical Research Communications, Vol. 187, No. 3, 1523-1528 (1992). The foregoing references, and all other references cited in the present application, are incorporated herein by reference.
- It would be desirable then, to provide an alternative method of capping failed sequences in polynucleotide formation. It would further be desirable to provide such a method which can be used in the fabrication of polynucleotide arrays and can provide failed sequences and interfeature areas with a functional group of the same type as provided by the functionalized surface.
- The present invention then, provides a method of comprising coupling coupling a hydroxy group of a moiety to a β-phospho or β-phosphite (such as a β-phosphoramidyl), protected alcohol, so as to form the corresponding phosphate or phosphite between the hydroxy and phospho or phosphite groups.
- The invention may include the step of oxidizing any phosphorous ester linkage formed other than a phosphate (for example, phosphite) to the corresponding phosphate. The resulting compound (containing the phosphate group) may then be hydrolyzed to deprotect the protected alcohol and cleave the phosphate from the moiety so as to regenerate the hydroxy group of the moiety.
- In another aspect, the present invention provides a method of protecting and de-protecting a hydroxy group of a moiety. In this aspect, the hydroxy group may be protected as described above, and de-protected by hydrolyzing the resulting compound to deprotect the protected alcohol and cleave the phosphate from the moiety so as to regenerate the hydroxy group of the moiety. The de-protection may be performed under suitable conditions, such as those described in deBear et al., cited above. For example, the hydrolysis may be performed under alkaline conditions.
- In one aspect, the above method is applied to a method of synthesizing oligonucleotides on a substrate carrying substrate bound moieties each with a hydroxy group (such as a functionalized substrate surface or a hydroxy group of a substrate bound nucleotide). In this aspect, in a coupling step a first nucleoside carrying a phospho or phosphite group is coupled to the hydroxy group of at least some of the substrate bound moieties in the usual manner. The first nucleoside has a protected hydroxy which can be deprotected under first deprotection conditions. In the case of phosphoramidite chemistry, this coupling step results in forming the corresponding phosphite between the hydroxy groups of the substrate bound moieties and the phosphoramidyl groups of the first phosphoramidite. At least some of the substrate bound moieties which failed to couple with the nucleoside phosphoramidite are protected by exposing them to a β- or γ-phosphoramidyl, protected alcohol, in the manner described above, which protected alcohol can be deprotected under second deprotection conditions but not the first deprotection conditions. In the case of phosphoramidite chemistry, this forms the corresponding phosphite between the hydroxy of those substrate bound moieties, and phosphoramidyl group of the β- or γ-phosphoramidyl, protected alcohol.
- The oligonucleotide synthesis method of the present invention may include, following the foregoing, a deprotection step is performed in which the substrate is exposed to the first deprotection conditions to deprotect the protected hydroxy of the coupled nucleoside in a manner already described. The sequence of the coupling and de-protecting steps, may be repeated as often as required to form a desired polynucleotide, with the deprotected hydroxy of the coupled nucleoside from the deprotection step in one cycle of the steps, serving as the hydroxy group of substrate bound moieties in the next cycle. When all desired cycles are complete, the substrate may be exposed to the second deprotection conditions to de-protect failed sequences by hydrolysis in the manner already described, so as to regenerate the hydroxy group of the substrate bound moiety. It will be understood, of course, that there may be other optional steps provided in each cycle or at the end of all desired cycles. For example, an oxidation step may be provided to oxidize internucleoside phosphites to the more stable corresponding phosphates, and one or more washing steps may also be provided.
- The present invention further includes, in another aspect, a method of fabricating an addressable array of polynucleotides on a substrate carrying substrate bound moieties each with a hydroxy group. This method includes, at each of multiple different substrate addresses, executing the above described olignonucleotide synthesis method of the present invention (particularly, including the described protecting and de-protecting steps). The phosphoramidites to be coupled at respective addresses may, for example, be deposited as droplets at those addresses, and wherein in the protecting step at least inter-address areas (and preferably both address and inter-address areas) are exposed to the β- or γ-phospho or phosphite (for example, phosphoramidyl), protected alcohol.
- The various aspects of the present invention can provide any one or more of a number of useful benefits. For example, an alternative method of capping failed sequences in polynucleotide formation is provided which does not require use of acetic anhydride. The method can be used in the fabrication of polynucleotide arrays and can provide failed sequences and interfeature areas with a functional group of the same type as provided by the functionalized surface.
- FIGS. 1 and 2 illustrate known schemes in the use of universal supports for polynucleotide synthesis, as discussed in the “Background” section above;
- FIG. 3 illustrates a substrate carrying multiple arrays, such as may be fabricated by methods of the present invention;
- FIG. 4 is an enlarged view of a portion of FIG. 3 showing multiple spots or features of one array;
- FIG. 5 is an enlarged illustration of a portion of the substrate of FIG. 3;
- FIG. 6 is a schematic illustrating in general a capping and de-capping method of the present invention; and
- FIG. 7 is a schematic illustrating a specific capping and de-capping method of the present invention.
- To facilitate understanding, identical reference numerals have been used, where practical, to designate identical elements that are common to the figures.
- Throughout the present application, unless a contrary intention appears, the following terms refer to the indicated characteristics. A “biopolymer” is a polymer of one or more types of repeating units. Biopolymers are a type of polymer found in biological systems and particularly include peptides or polynucleotides, as well as such compounds composed of or containing amino acid or nucleotide analogs or non-nucleotide groups. This includes polynucleotides in which the conventional backbone has been replaced with a non-naturally occurring or synthetic backbone, and nucleic acids in which one or more of the conventional bases has been replaced with a synthetic base capable of participating in Watson-Crick type hydrogen bonding interactions. Polynucleotides include single or multiple stranded configurations, where one or more of the strands may or may not be completely aligned with another. While probes and targets of the present invention will typically be single-stranded, this is not essential. A “nucleotide” refers to a sub-unit of a nucleic acid and has a phosphate group, a 5 carbon sugar and a nitrogen containing base, as well as analogs of such sub-units. Specifically, a “biopolymer” includes DNA (including cDNA), RNA and oligonucleotides, regardless of the source. An “oligonucleotide” generally refers to a nucleotide multimer of about 10 to 100 nucleotides in length, while a “polynucleotide” includes a nucleotide multimer having any number of nucleotides. A “biomonomer” references a single unit, which can be linked with the same or other biomonomers to form a biopolymer (for example, a single amino acid or nucleotide with two linking groups one or both of which may have removable protecting groups). A biomonomer fluid or biopolymer fluid reference a liquid containing either a biomonomer or biopolymer, respectively (typically in solution). An “array”, unless a contrary intention appears, includes any one or two dimensional arrangement of addressable regions bearing a particular chemical moiety to moieties (for example, biopolymers such as polynucleotide sequences) associated with that region. An array is “addressable” in that it has multiple regions of different moieties (for example, different polynucleotide sequences) such that a region (a “feature” or “spot” of the array) at a particular predetermined location (an “address”) on the array will detect a particular target or class of targets (although a feature may incidentally detect non-targets of that feature). In the case of an array, the “target” will be referenced as a moiety in a mobile phase (typically fluid), to be detected by probes (“target probes”) which are bound to the substrate at the various regions. However, either of the “target” or “target probes” may be the one which is to be evaluated by the other (thus, either one could be an unknown mixture of polynucleotides to be evaluated by binding with the other). An “array layout” refers to one or more characteristics of the array, such as feature positioning, feature size, and some indication of a moiety at a given location. “Hybridizing” and “binding”, with respect to polynucleotides, are used interchangeably. A “phospho” group includes a phosphodiester, phosphotriester, and H-phosphonate groups as defined in connection with formula (I) above, while a “phosphite” includes a phosphoramidite (in the case of either a phospho or phosphite group, a moiety other than the illustrated substituted 5-membered furyl ring may be attached to O of the phospho or phosphite group which links between the furyl ring shown in formula (I) and the P atom). A “lower” alkyl, carboxylate or other “lower” group, references such a group having from 1 to 6 carbon atoms. A “protecting group” is used in the conventional chemical sense to reference a group which reversibly renders unreactive a functional group under specified conditions of a desired reaction. After the desired reaction, protecting groups may be removed to deprotect the protected functional group. To avoid confusion, the —OH group of a nucleoside monomer (typically, the 3′ or 5′ —OH of a nucleoside phosphoramidite) which is protected then deprotected during each cycle of polynucleotide coupling, is generally referenced as a “hydroxy”, while —OH of the nucleoside monomer which is generally only deprotected after the desired polynucleotide synthesis is complete, is referenced as an “alcohol” group (which is typically protected until after such completion). All protecting groups should be removable (and hence, labile) under conditions which do not degrade a substantial proportion of the polynucleotides being synthesized. It is also possible in the present invention that steps may be executed in different sequence where this is logically possible. However, the sequence described below is preferred.
- It will also be appreciated that throughout the present application, that words such as “upper”, “lower” are used in a relative sense only. A “set” may have one type of member or multiple different types. “Fluid” is used herein to reference a liquid. Reference to a singular item, includes the possibility that there are plural of the same items present.
- Referring first to FIGS. 3-5, typically methods and apparatus of the present invention generate or use a contiguous
planar substrate 10 carrying one ormore arrays 12 disposed across afirst surface 11 a ofsubstrate 10 and separated byinter-array areas 13. The arrays onsubstrate 10 can be designed for testing against any type of sample, whether a trial sample, reference sample, a combination of them, or a known mixture of polynucleotides (in which latter case the arrays may be composed of features carrying unknown sequences to be evaluated). While tenarrays 12 are shown in FIG. 5 and the different embodiments described below may use substrates with particular numbers of arrays, it will be understood thatsubstrate 10 and the embodiments to be used with it, may use any number of desiredarrays 12. Similarly,substrate 10 may be of any shape, and any apparatus used with it adapted accordingly. Depending upon intended use, any or all ofarrays 12 may be the same or different from one another and each will contain multiple spots or features 16 of biopolymers in the form of polynucleotides. A typical array may contain from more than ten, more than one hundred, more than one thousand or ten thousand features, or even more than from one hundred thousand features. All of thefeatures 16 may be different, or some or all could be the same. In the embodiment illustrated, there areinterfeature areas 17 between features, which do not carry any polynucleotide. It will be appreciated though, that theinterfeature areas 17 could be of various sizes and configurations. Each feature carries a predetermined polynucleotide (which includes the possibility of mixtures of polynucleotides). As per usual, A, C, G, T represent the usual nucleotides, while L represents a linker bound tosubstrate 10. It will be appreciated that there need not be anyspace separating arrays 12 from one another, nor features 16 within an array from one another. However, in the preferred case wherearrays 12 are formed by the in situ method by depositing droplets of reagents in each step such as by using a pulse jet such as an inkjet type head, suchinterfeature areas 17 will typically be present. -
- Wherein: Y—O— is a phospho or phosphite group as defined above; any of R2, R3, R4 or R5 may be the same or different and may be selected from H, substituted or unsubstituted alkyl or alkoxyl groups (particularly lower alkyl groups), or any two of them may together form a carbocyclic ring or heterocyclic ring (including those having one or two heteroatoms selected from N or O) such as a five to seven membered ring (for example, furyl); and X represents an alcohol protecting group. γ-phospho or γ-phosphite compounds have the same formula as (II) above, except that there is an additional C (substituted or unsubstituted with one to two groups, the same or different selected from any of those groups which R2 to R5 may represent) between the Cs to which R2 and R4 are bonded. Particularly preferred are those compounds of formula (II) in which two of R2 to R5 form a ring, particularly a 5 membered heterocyclic ring, such as furyl or pyryl (particularly where the compound is a furanose, or pyranose derivative). In cases where a ring is present, it is preferred that Y—O— and X—O— are cis with respect to one another. Suitable protecting groups on the alcohol include those such as described in “Protective groups in organic synthesis” by Theodora W. Greene and Peter G. M. Wuts , Wiley-interscience ISBN 0-471-62301-6 p68-117. The protecting group on the alcohol group substantially prevents one monomer from linking with another through that alcohol group during growing of the polymer chain.
-
- Alternatively X may, for example, be an H-phosphonate, Me-phosphonate, or phosphodiester group.
- In general the β- or γ-phospho or phosphite, protected alcohols can be prepared by methods such as described by Toshiki Tanaka and Robert Letsinger, Nucleic Acids Research, 10, 3249-3260, 1982. The β- or γ-phosphoramidyl, protected alcohols, in particular can be prepared by the method described in
column 11 and 12 of U.S. Pat. No. 5,681,945 up toproduct 2, then the remaining alcohol is converted to the cyanoethyl phosphoramidite using 2-cyanoethyl-N,N,N′,N′-tetraisopropylphosphorodiamidite (A. Kraszewski, K. E. Norris, Nucleic Acids Res., 18, 177 (1987)). The protected nucleoside (1 mmol) and tetrazole (0.5 mmol) are dried under vaccum for 4 hours. These reagents are then dissolved in CH2Cl2/THF (95:5, 20 ml), and 2-cyanoethyl-N,N,N′,N′-tetraisopropylphosphorodiamidite (1.3 mmol) is added drop-wise under argon. The reaction is stirred 20 hours at room temperature. Triethylamine (0.5 ml) is added to the reaction mixture. The mixture is diluted with CH2Cl2 (20 ml) and extracted with 2% aqueous Na2CO3 (30 ml) followed by brine (30 ml). The aqueous layers are back extracted with CH2Cl2 (30 ml). The combined organic layers are dried over Na2SO4. The organic fraction is concentrated to 15 ml and product is precipitated from cold hexane. The precipitate is dried under vaccum. - A typical execution of a method of the present invention is illustrated using a β-phospho or β-phosphite compound of formula (II). First, normally
substrate 10 will have been functionalized by providing it with substrate bound moieties with hydroxy groups. Suitable techniques for functionalizing substrates with such linking moieties are described, for example, in Southern, E. M., Maskos, U. and Elder, J. K., Genomics, 13, 1007-1017, 1992. In the manufacture of an array as illustrate in FIGS. 3-5 this step is normally carried out by exposing the substrate 10 (in particular,first surface 11 a of substrate 10) to functionalizing reagents as described in the foregoing references. Next, a nucleoside phospho or phosphite compound is then deposited as a droplet of solution onto each address onsubstrate 10 at which it is desired to form afeatures 16, using any suitable droplet deposition technique as discussed above, such as a pulse jet (for example, and inkjet head). Such a nucleoside compound typically has the phospho or phosphite group at one of the 3′ or 5′ positions, depending upon which direction (3′ to 5′, or 5′ to 3′) it is desired to have the polynucleotide synthesis proceed, and a protected hydroxy group at the other one of those positions. Nucleoside phosphoramidites are preferred. Suitable protecting groups are described in “Protective Groups in Organic Synthesis” by T. W. Green, Wiley Interscience. The protecting group should be capable of removal to deprotect the hydroxy group, under first deprotection conditions. The first deprotection conditions preferably are acidic conditions, and thus acid labile protecting groups are preferred. Acid labile protecting groups include those such as tetrahydropyranyl groups, e.g. tetrahydropyran-2-yl and 4-methoxytetrahydropyran-2-yl; optionally substituted trityl groups, for example a monomethoxytrityl for oligoribonucleotide synthesis and a dimethoxytrityl for oligodeoxyribonucleotide synthesis, pixyl; isobutyloxycarbonyl; t-butyl; and dimethylsilyl. The preferred acid labile protecting group is a dimethoxytrityl group, especially 4,4′-dimethoxytrityl. Conventional known reaction conditions may be used. As a result, the nucleoside compound is coupled to the hydroxy groups of at least some of the substrate bound linking groups, by forming the corresponding phospho or phosphite between the hydroxy groups of the substrate bound linkers and the phospho or phosphite group (for example, phosphoramidyl group) of the nucleoside compound. Particularly in the case of phosphoramidites, the reaction is complete very rapidly at room temperature of about 20° C. (for example, in one or two seconds). - The coupling product is then oxidized using known conditions (described in one or more of the references cited above) to form the more stable corresponding phosphate bond between the nucleoside and linker. This is preferably performed by exposing substrate 10 (in particular, the entire
first surface 11 a) to the oxidizing solution, for example, by flowing such a solution acrossfirst surface 11 a. Note that this oxidation step is optional, although preferred. - At this point, the capping of substrate bound linkers which failed to couple with a nucleoside compound, can then be accomplished by exposing substrate 10 (in particular, the entire
first surface 11 a) to such reagent. This also is preferably accomplished by flowing a solution containing any of the capping reagents of formula (II) described above acrossfirst surface 11 a. Suitable solvents and reactions conditions include any of those which may be used to couple analogous nucleoside phospho or phosphite compounds to the linker, as described above. By analogous in this context, is referenced the same phospho or phosphite group being present. Note that the alcohol protecting group, X, should be one which is removed under second deprotection conditions but not removed under the first deprotection conditions. By “not removed under the first deprotection conditions” is referenced one of which no more than 40%, 20%, or 10% is removed (and preferably no more than 5%, and most preferably no more than 2%). The second deprotection conditions are preferably alkaline, and thus X is preferably an alkaline labile deprotecting group. Suitable alkaline deprotecting groups are also described in “Protective Groups in Organic Synthesis”, supra. Examples of protecting groups X include benzoyl, acetyl, p-nitrophenyl carbonate groups, silyl protecting groups (for example, as dimethyl silyl) which can be removed with a fluoride anion such as tetrabutylammonium fluoride. Particularly preferable are ones which provide, on the protected alcohol, a carboxylate group such as an alkyl carboxylate group (particularly a lower carboxylate group), such as acetate. - Following the coupling, oxidation, and capping steps as described above, substrate 10 (particularly
first surface 11 a) may then be exposed to the first deprotection conditions (preferably by exposure to an acidic solution as already described), to deprotect the protected 3′ or 5′ hydroxy of the coupled nucleoside. The required solution is, for example, flowed acrossfirst surface 11 a. The steps of coupling, oxidation, capping, and deprotection of the coupled nucleoside may then be repeated until eachfeature 16 has the desired polynucleotide sequence. Note that in each repetition of the cycle of steps, the deprotected hydroxy group of a coupled nucleoside in a given cycle, serves as the hydroxy group of substrate bound moieties in the next cycle. - At this point, the substrate 10 (particularly
first surface 11 a) is exposed to the second deprotection conditions. This also may be done by flowing the required alkaline solution across the entirefirst surface 11 a. As a result, failed sequences resulting from each cycle of the steps, will be deprotected, as illustrated in FIG. 6, by hydrolysis to deprotect the protected alcohol of such sequences and cleave the phosphate from the substrate bound moiety (whether a nucleotide or linker) so as to regenerate the hydroxy group of the substrate bound moiety. - A particular example of the method of the present invention is illustrate in FIG. 7 (in which “R” is any one of the lower alkyls, particularly methyl). The illustrate steps may be executed as follows. During the capping step, an equal amount of a solution of a capping phosphoramidite and an activator (such as tetrazole) are flooded over the surface. The solutions are either premixed or mixed on the surface. After 1 minute the solution is removed from the surface and an oxidation solution is flooded over the surface. At the end of the synthesis, the DNA array is removed from the synthesizer and is dipped in 600 ml of a 1:1 solution of a 40% methylamine in water and 28% ammonia in water. This solution removes the protecting groups on the DNA and the capping agent. Then the alcoholate generated on the capping agent attacks the phosphorus leading to a cleavage of the P—O bond. After 16 hours at room temperature the arrays are removed from the solution and washed with water. The DNA array is ready to be use. In the case where other capping agents are used in accordance with the methods of the present invention, the foregoing conditions can be adjusted accordingly.
- Various modifications to the particular embodiments described above are, of course, possible. Accordingly, the present invention is not limited to the particular embodiments described in detail above.
Claims (24)
1. A method, comprising:
(a) coupling a hydroxy group of a moiety to a β- or γ-phosphoramidyl, protected alcohol, so as to form the corresponding phosphite between the hydroxy and phosphoramidyl groups;
(b) oxidizing the phosphite to a phosphate; and
(c) deprotecting the hydroxy group by hydrolyzing the resulting compound to deprotect the protected alcohol and cleave the phosphate from the moiety so as to regenerate the hydroxy group of the moiety.
2. A method according to claim 1 wherein a β-phosphoramidyl, protected alcohol is coupled to the hydroxy group of the moiety.
3. A method according to claim 1 wherein the hydrolysis is performed under alkaline conditions.
4. A method of synthesizing oligonucleotides on a substrate carrying substrate bound moieties each with a hydroxy group, comprising:
(a) coupling a nucleoside phosphoramidite to the hydroxy group of at least some of the substrate bound moieties by forming the corresponding phosphite between the hydroxy groups of the substrate bound moieties and the phosphoramidyl groups of the nucleoside phosphoramidite, wherein the nucleoside has a protected hydroxy which can be deprotected under first deprotection conditions; and
(b) coupling at least some of the substrate bound moieties which failed to couple with the nucleoside phosphoramidite by exposing them to a β- or γ-phosphoramidyl, protected alcohol so as to form the corresponding phosphite between the hydroxy of those substrate bound moieties and phosphoramidyl group of the β- or γ-phosphoramidyl, protected alcohol, wherein the protected alcohol can be deprotected under second deprotection conditions but not under the first deprotection conditions,.
5. A method according to claim 4 further comprising:
(c) oxidizing phosphites formed in steps (a) and (b) to phosphates.
6. A method according to claim 5 further comprising:
(d) following steps (a) and (b), exposing the substrate to the first deprotection conditions to deprotect the protected hydroxy of the coupled nucleoside;
(e) repeating steps (a) to (d) wherein the deprotected hydroxy of the coupled nucleoside from step (d) in one cycle of the steps, serves as the hydroxy group of substrate bound moieties in the next cycle; and
(f) following step (e), exposing the substrate to the second deprotection conditions to de-protect failed sequences by hydrolysis of the protected alcohol and cleavage of the phosphate from the substrate bound moiety so as to regenerate the hydroxy group of the substrate bound moiety.
7. A method according to claim 6 wherein the second deprotection conditions are alkaline conditions.
8. A method according to claim 6 wherein the first deprotection conditions are acidic conditions.
9. A method according to claim 4 wherein the at least some of the substrate bound moieties which failed to couple are exposed to a β-phosphoramidyl, protected alcohol.
10. A method of synthesizing oligonucleotides on a substrate carrying substrate bound moieties each with a hydroxy group, comprising:
(a) coupling a nucleoside phosphoramidite to the hydroxy group of at least some of the substrate bound moieties, which first nucleoside has a protected hydroxy which can be deprotected under first deprotection conditions, by forming the corresponding phosphite between the hydroxy groups of the substrate bound moieties and the phosphoramidyl groups of the first nucleoside phosphoramidite, wherein the nucleoside has a protected hydroxy which can be deprotected under first deprotection conditions;
(b) protecting at least some of the substrate bound moieties which failed to couple with the nucleoside phosphoramidite by exposing them to a β- or γ-phosphoramidyl, protected alcohol, which protected alcohol can be deprotected under second deprotection conditions but not the first deprotection conditions, so as to form the corresponding phosphite between the hydroxy of those substrate bound moieties, and phosphoramidyl group of the β- or γ-phosphoramidyl, protected alcohol, wherein the protected alcohol can be deprotected under second deprotection conditions but not under the first deprotection conditions;
(c) oxidizing phosphites formed in steps (a) and (b) to phosphates;
(d) following steps (a) and (b), exposing the substrate to the first deprotection conditions to deprotect the protected hydroxy of the coupled nucleoside;
(e) repeating steps (a) to (d) wherein the deprotected hydroxy of the coupled nucleoside from step (d) in one cycle of the steps, serves as the hydroxy group of substrate bound moieties in the next cycle; and
(f) following step (e), exposing the substrate to the second deprotection conditions to de-protect failed sequences by hydrolysis of the protected alcohol and cleavage of the phosphate from the substrate bound moiety so as to regenerate the hydroxy group of the substrate bound moiety;
wherein the protected alcohol of the β- or γ-phosphoramidyl, protected alcohol, has a carboxylate group.
11. A method according to claim 10 wherein the β- or γ-phosphoramidyl, protected alcohol, is a carbocyclic or heterocyclic compound.
12. A method according to claim 11 wherein the phosphoramidyl and protected alcohol are cis.
13. A method according to claim 11 wherein the β- or γ-phosphoramidyl, protected alcohol, is a furanose or pyranose derivative.
14. A method according to claim 13 wherein the β- or γ-phosphoramidyl, protected alcohol, is a 3-carboxylate-4-phosphoramidylfuran.
15. A method according to claim 14 wherein the β- or γ-phosphoramidyl, protected alcohol, is a 2,5-dialkoxy-3-carboxylate-4-phosphoramidylfuran.
16. A method of fabricating an addressable array of polynucleotides on a substrate carrying substrate bound moieties each with a hydroxy group, comprising, at each of multiple different substrate addresses:
(a) coupling a nucleoside phosphoramidite to the hydroxy group of at least some of the substrate bound moieties by forming the corresponding phosphite between the hydroxy groups of the substrate bound moieties and the phosphoramidyl groups of the first phosphoramidite, wherein the nucleoside has a protected hydroxy which can be deprotected under first deprotection conditions,; and
(b) protecting at least some of the substrate bound moieties which failed to couple with the nucleoside phosphoramidite by exposing them to a β- or γ-phosphoramidyl, protected alcohol so as to form the corresponding phosphite between the hydroxy of those substrate bound moieties, and phosphoramidyl group of the β- or γ-phosphoramidyl, protected alcohol, wherein the protected alcohol can be deprotected under second deprotection conditions but not the first deprotection conditions;
(c) oxidizing phosphites formed in steps (a) and (b) to phosphates.
(d) following steps (a) and (b), exposing the addresses to the first deprotection conditions to deprotect the protected hydroxy of the coupled nucleoside;
(e) repeating steps (a) to (d) wherein the deprotected hydroxy of the coupled nucleoside from step (d) in one cycle of the steps, serves as the hydroxy group of substrate bound moieties in the next cycle, so as to form different polynucleotide sequences at different addresses; and
(f) following step (e), exposing the substrate to the second deprotection conditions to de-protect failed sequences by hydrolysis of the protected alcohol and cleavage of the phosphate from the substrate bound moiety so as to regenerate the hydroxy group of the substrate bound moiety.
17. A method according to claim 16 wherein in step (a) the phosphoramidites to be coupled at respective addresses are deposited as droplets at those addresses, and wherein in step (b) both the addresses and inter-address areas are exposed to the β- or γ-phosphoramidyl, protected alcohol.
18. A method according to claim 16 wherein in step (b) all of the substrate is simultaneously exposed to the β- or γ-phosphoramidyl, protected alcohol.
19. A method according to claim 18 wherein in step (f) all of the substrate is simultaneously exposed to the β- or γ-phosphoramidyl, protected alcohol.
20. A method according to claim 16 wherein the second deprotection conditions are alkaline conditions.
21. A method according to claim 16 wherein the at least some of the substrate bound moieties which failed to couple are exposed to a β-phosphoramidyl, protected alcohol.
22. A method of fabricating an addressable array of polynucleotides on a substrate carrying substrate bound moieties each with a hydroxy group, comprising, at each of multiple different substrate addresses:
(a) coupling a nucleoside phosphoramidite to the hydroxy group of at least some of the substrate bound moieties by forming the corresponding phosphite between the hydroxy groups of the substrate bound moieties and the phosphoramidyl groups of the first phosphoramidite, wherein the nucleoside has a protected hydroxy which can be deprotected under first deprotection conditions,; and
(b) coupling at least some of the substrate bound moieties which failed to couple with the nucleoside phosphoramidite by exposing them to a β- or γ-phosphoramidyl, protected alcohol so as to form the corresponding phosphite between the hydroxy of those substrate bound moieties, and phosphoramidyl group of the β- or γ-phosphoramidyl, protected alcohol, wherein the protected alcohol can be deprotected under second deprotection conditions but not the first deprotection conditions;
(c) oxidizing phosphites formed in steps (a) and (b) to phosphates.
(d) following steps (a) and (b), exposing the addresses to the first deprotection conditions to deprotect the protected hydroxy of the coupled nucleoside;
(e) repeating steps (a) to (d) wherein the deprotected hydroxy of the coupled nucleoside from step (d) in one cycle of the steps, serves as the hydroxy group of substrate bound moieties in the next cycle, so as to form different polynucleotide sequences at different addresses; and
(f) following step (e), exposing the substrate to the second deprotection conditions to de-protect failed sequences by hydrolysis of the protected alcohol and cleavage of the phosphate from the substrate bound moiety so as to regenerate the hydroxy group of the substrate bound moiety;
wherein the nucleoside has a carboxylate group.
23. A method according to claim 22 wherein the β- or γ-phosphoramidyl, protected alcohol, is a furanose or pyranose derivative.
24. A method according to claim 22 wherein the β- or γ-phosphoramidyl, protected alcohol, is a 2,5-dialkoxy-3-carboxylate-4-phosphoramidylfuran.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/245,211 US20030028012A1 (en) | 1999-10-18 | 2002-09-17 | Polynucleotide synthesis |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/420,099 US6451998B1 (en) | 1999-10-18 | 1999-10-18 | Capping and de-capping during oligonucleotide synthesis |
| US10/245,211 US20030028012A1 (en) | 1999-10-18 | 2002-09-17 | Polynucleotide synthesis |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/420,099 Continuation US6451998B1 (en) | 1999-10-18 | 1999-10-18 | Capping and de-capping during oligonucleotide synthesis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20030028012A1 true US20030028012A1 (en) | 2003-02-06 |
Family
ID=23665077
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/420,099 Expired - Fee Related US6451998B1 (en) | 1999-10-18 | 1999-10-18 | Capping and de-capping during oligonucleotide synthesis |
| US10/245,211 Abandoned US20030028012A1 (en) | 1999-10-18 | 2002-09-17 | Polynucleotide synthesis |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/420,099 Expired - Fee Related US6451998B1 (en) | 1999-10-18 | 1999-10-18 | Capping and de-capping during oligonucleotide synthesis |
Country Status (1)
| Country | Link |
|---|---|
| US (2) | US6451998B1 (en) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2533173A (en) | 2013-08-05 | 2016-06-15 | Twist Bioscience Corp | De Novo synthesized gene libraries |
| CA2975855C (en) | 2015-02-04 | 2025-09-23 | Twist Bioscience Corporation | Compositions and methods for synthetic gene assembly |
| WO2016126882A1 (en) | 2015-02-04 | 2016-08-11 | Twist Bioscience Corporation | Methods and devices for de novo oligonucleic acid assembly |
| WO2016172377A1 (en) | 2015-04-21 | 2016-10-27 | Twist Bioscience Corporation | Devices and methods for oligonucleic acid library synthesis |
| AU2016324296A1 (en) | 2015-09-18 | 2018-04-12 | Twist Bioscience Corporation | Oligonucleic acid variant libraries and synthesis thereof |
| US11512347B2 (en) | 2015-09-22 | 2022-11-29 | Twist Bioscience Corporation | Flexible substrates for nucleic acid synthesis |
| WO2017095958A1 (en) | 2015-12-01 | 2017-06-08 | Twist Bioscience Corporation | Functionalized surfaces and preparation thereof |
| CA3034769A1 (en) | 2016-08-22 | 2018-03-01 | Twist Bioscience Corporation | De novo synthesized nucleic acid libraries |
| JP6871364B2 (en) | 2016-09-21 | 2021-05-12 | ツイスト バイオサイエンス コーポレーション | Nucleic acid-based data storage |
| AU2017378492B2 (en) | 2016-12-16 | 2022-06-16 | Twist Bioscience Corporation | Variant libraries of the immunological synapse and synthesis thereof |
| EP4556433A3 (en) | 2017-02-22 | 2025-08-06 | Twist Bioscience Corporation | Nucleic acid based data storage |
| AU2018234629A1 (en) | 2017-03-15 | 2019-10-17 | Twist Bioscience Corporation | Variant libraries of the immunological synapse and synthesis thereof |
| WO2018231864A1 (en) | 2017-06-12 | 2018-12-20 | Twist Bioscience Corporation | Methods for seamless nucleic acid assembly |
| KR102784398B1 (en) | 2017-06-12 | 2025-03-19 | 트위스트 바이오사이언스 코포레이션 | Methods for seamless nucleic acid assembly |
| GB2581620A (en) | 2017-09-11 | 2020-08-26 | Twist Bioscience Corp | GPCR binding proteins and synthesis thereof |
| GB2583590A (en) | 2017-10-20 | 2020-11-04 | Twist Bioscience Corp | Heated nanowells for polynucleotide synthesis |
| KR102804057B1 (en) | 2018-01-04 | 2025-05-07 | 트위스트 바이오사이언스 코포레이션 | DNA-based digital information storage |
| EP3814497A4 (en) | 2018-05-18 | 2022-03-02 | Twist Bioscience Corporation | POLYNUCLEOTIDES, REAGENTS, AND METHODS FOR NUCLEIC ACID HYBRIDIZATION |
| CA3124980A1 (en) | 2018-12-26 | 2020-07-02 | Twist Bioscience Corporation | Highly accurate de novo polynucleotide synthesis |
| SG11202109283UA (en) | 2019-02-26 | 2021-09-29 | Twist Bioscience Corp | Variant nucleic acid libraries for antibody optimization |
| WO2020176678A1 (en) | 2019-02-26 | 2020-09-03 | Twist Bioscience Corporation | Variant nucleic acid libraries for glp1 receptor |
| EP3987019A4 (en) | 2019-06-21 | 2023-04-19 | Twist Bioscience Corporation | BARCODE-BASED NUCLEIC ACID SEQUENCE ARRANGEMENT |
| CA3155630A1 (en) | 2019-09-23 | 2021-04-01 | Twist Bioscience Corporation | Variant nucleic acid libraries for single domain antibodies |
| EP4464827A3 (en) | 2019-09-23 | 2025-02-26 | Twist Bioscience Corporation | Variant nucleic acid libraries for crth2 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US4500707A (en) | 1980-02-29 | 1985-02-19 | University Patents, Inc. | Nucleosides useful in the preparation of polynucleotides |
| US4415732A (en) | 1981-03-27 | 1983-11-15 | University Patents, Inc. | Phosphoramidite compounds and processes |
| WO1986007362A1 (en) | 1985-06-14 | 1986-12-18 | University Patents, Inc. | Method for synthesizing deoxyoligonucleotides |
| US5153319A (en) | 1986-03-31 | 1992-10-06 | University Patents, Inc. | Process for preparing polynucleotides |
| US4816571A (en) | 1987-06-04 | 1989-03-28 | Applied Biosystems, Inc. | Chemical capping by phosphitylation during oligonucleotide synthesis |
| US5218103A (en) | 1988-05-26 | 1993-06-08 | University Patents, Inc. | Nucleoside thiophosphoramidites |
| US5049656A (en) * | 1988-12-21 | 1991-09-17 | Board Of Regents Of The University Of Nebraska | Sequential peptide and oligonucleotide syntheses using immunoaffinity techniques |
| GB9207381D0 (en) | 1992-04-03 | 1992-05-13 | Ici Plc | Synthesis of oligonucleotides |
| GB9207380D0 (en) | 1992-04-03 | 1992-05-13 | Ici Plc | Compounds |
| FR2714061B1 (en) | 1993-12-16 | 1996-03-08 | Genset Sa | Process for the preparation of polynucleotides on solid support and apparatus allowing its implementation. |
| US5908926A (en) | 1995-03-16 | 1999-06-01 | Duke University | 5'to 3' nucleic acid synthesis using 3'-photoremovable protecting group |
| US5856464A (en) | 1995-06-07 | 1999-01-05 | Lajolla Pharmaceutical Company | Selective capping solution phase oligonucleotide synthesis |
| US5684143A (en) | 1996-02-21 | 1997-11-04 | Lynx Therapeutics, Inc. | Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates |
| US5723294A (en) | 1996-03-05 | 1998-03-03 | Gull Laboratories | Methods for detection and discrimination of multiple analytes using fluorescent technology |
-
1999
- 1999-10-18 US US09/420,099 patent/US6451998B1/en not_active Expired - Fee Related
-
2002
- 2002-09-17 US US10/245,211 patent/US20030028012A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US6451998B1 (en) | 2002-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6451998B1 (en) | Capping and de-capping during oligonucleotide synthesis | |
| AU2023203187B2 (en) | Compositions And Methods For Chemical Cleavage And Deprotection Of Surface-Bound Oligonucleotides | |
| US6300137B1 (en) | Method for synthesizing a specific, surface-bound polymer uniformly over an element of a molecular array | |
| US7553958B2 (en) | Linkers and co-coupling agents for optimization of oligonucleotide synthesis and purification on solid supports | |
| EP1176151B1 (en) | Synthesis of polynucleotides using combined oxidation/deprotection chemistry | |
| US20030036066A1 (en) | Linker phosphoramidites for oligonucleotide synthesis | |
| EP2159290A1 (en) | Method of producing microarray having immobilized double-stranded nucleic acid probe including double-stranded region and single-stranded region | |
| CA3067434C (en) | Compositions and methods for chemical cleavage and deprotection of surface-bound oligonucleotides | |
| HK40102983A (en) | Chemical cleavage and deprotection | |
| HK40042324B (en) | Compositions and methods for chemical cleavage and deprotection of surface-bound oligonucleotides | |
| HK40042324A (en) | Compositions and methods for chemical cleavage and deprotection of surface-bound oligonucleotides | |
| JPH04330093A (en) | Production of oligoribonucleotide | |
| WO2005000859A2 (en) | Novel reagent compounds and methods of making and using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |